Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-3032
- Development stage
- Phase 1
- Lead developer
- Hengrui Therapeutics
- Administration
- Intravenous
01
Overview
SHR-3032 is a biological product developed by Guangdong Hengrui Pharmaceutical. It is being investigated for the prevention of graft rejection, primarily in the context of transplantation. The drug is administered intravenously and has completed Phase 1 clinical trials evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. The precise mechanism of action remains undisclosed or unknown as of the latest available data[1][2][10].
Beyond the preview
Go deeper on SHR-3032.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-3032.